Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Total Debt (2017 - 2024)

Organogenesis Holdings (ORGO) has 8 years of Total Debt data on record, last reported at $62.1 million in Q3 2024.

  • For Q3 2024, Total Debt fell 8.11% year-over-year to $62.1 million; the TTM value through Sep 2024 reached $62.1 million, down 8.11%, while the annual FY2023 figure was $66.2 million, 6.41% down from the prior year.
  • Total Debt reached $62.1 million in Q3 2024 per ORGO's latest filing, down from $63.5 million in the prior quarter.
  • Across five years, Total Debt topped out at $73.9 million in Q3 2021 and bottomed at $11.7 million in Q1 2020.
  • Average Total Debt over 5 years is $58.8 million, with a median of $66.2 million recorded in 2023.
  • The widest YoY moves for Total Debt: up 297.77% in 2020, down 74.07% in 2020.
  • A 5-year view of Total Debt shows it stood at $26.7 million in 2020, then skyrocketed by 175.35% to $73.4 million in 2021, then decreased by 3.62% to $70.8 million in 2022, then fell by 6.41% to $66.2 million in 2023, then fell by 6.21% to $62.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Total Debt were $62.1 million in Q3 2024, $63.5 million in Q2 2024, and $64.9 million in Q1 2024.